Research Topics
| Michael S SeamanSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogensMichael S Seaman
Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, 330 Brookline Ave RE 204, Boston, MA 02215, USA
Virology 367:175-86. 2007....
The neutralization properties of a HIV-specific antibody are markedly altered by glycosylation events outside the antigen-binding domainLuis R Miranda
Division of Hematology Oncology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
J Immunol 178:7132-8. 2007..These results suggest that structural features of the Ig molecule other than the primary sequence of the variable regions play a more prominent role in HIV neutralization than anticipated...- LabKey Server NAb: a tool for analyzing, visualizing and sharing results from neutralizing antibody assaysBritt Piehler
LabKey Software, Seattle, Washington 98102, USA
BMC Immunol 12:33. 2011..Updating all instances of such a macro with new techniques can be unwieldy and introduce non-uniformity across multi-lab teams. Using Excel also poses challenges in centrally storing, sharing and associating raw data files and results... - Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodiesMichael S Seaman
Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
J Virol 84:1439-52. 2010..These reference viruses can facilitate the systematic characterization of NAb responses elicited by candidate vaccine immunogens... - Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectorsSampa Santra
Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Vaccine 27:5837-45. 2009.... - Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administrationMarissa B Wilck
Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts, USA
J Infect Dis 201:1361-70. 2010..We conducted a clinical trial of the safety and immunogenicity of modified vaccinia Ankara (MVA) to examine the effects of dose and route of administration... - Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primatesSampa Santra
Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, RE113, P. O. Box 15732, Boston, MA 02215, USA
J Virol 79:6516-22. 2005..Therefore, administration of ADV5-based vectors in DNA-primed subjects may be a preferred use of this vaccine modality for generating long-term immune protection... - Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeysLauren E Grandpre
Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Boston, MA 02215, United States
Vaccine 27:1549-56. 2009..Together, these studies suggest that a multi-dose vaccine regimen utilizing up to four inoculations of MVA generates robust and durable antibody-mediated immunity comparable to that elicited by replication-competent VV... - Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeysDan H Barouch
Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Nat Med 16:319-23. 2010..Polyvalent mosaic antigens therefore represent a promising strategy to expand cellular immunologic vaccine coverage for genetically diverse pathogens such as HIV-1... - Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeysJinyan Liu
Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
Nature 457:87-91. 2009..These findings have important implications for the development of next-generation T-cell-based vaccine candidates for HIV-1... - Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeysDan H Barouch
Division of Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
Nature 482:89-93. 2012..These data demonstrate the proof-of-concept that optimized HIV-1 vaccine candidates can block acquisition of stringent, heterologous, neutralization-resistant virus challenges in rhesus monkeys... - Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeysWendy W Yeh
Division of Viral Pathogenesis, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
J Virol 84:6018-32. 2010..They also illustrate the capacity of the SIVmac quasispecies to modify antigenic determinants in response to very modest titers of neutralizing antibodies... - Preservation of functional virus-specific memory CD8+ T lymphocytes in vaccinated, simian human immunodeficiency virus-infected rhesus monkeysPaula M Acierno
Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02115, USA
J Immunol 176:5338-45. 2006.... - Envelope vaccination shapes viral envelope evolution following simian immunodeficiency virus infection in rhesus monkeysAravind Basavapathruni
Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
J Virol 84:953-63. 2010..These data show that env vaccination altered the focus of the antibody-mediated selection pressure on the evolution of envelope following SIV challenge... - Vaccine-elicited memory cytotoxic T lymphocytes contribute to Mamu-A*01-associated control of simian/human immunodeficiency virus 89.6P replication in rhesus monkeysMichael S Seaman
Beth Israel Deaconess Medical Center, Division of Viral Pathogenesis, 330 Brookline Ave. RE-113, Boston, MA 02215, USA
J Virol 79:4580-8. 2005..These data indicate that specific MHC class I alleles can confer protection in the setting of a pathogenic SHIV infection by their ability to elicit memory CTL following vaccination... - Dominant CD8+ T-lymphocyte responses suppress expansion of vaccine-elicited subdominant T lymphocytes in rhesus monkeys challenged with pathogenic simian-human immunodeficiency virusEdwin R Manuel
Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, E CLS Room 1043, Boston, Massachusetts 02215, USA
J Virol 83:10028-35. 2009..These findings suggest that immunodomination exerted by dominant responses during SHIV infection may diminish the breadth of recall responses primed during vaccination... - HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120James M Kovacs
Division of Molecular Medicine, Children s Hospital, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 109:12111-6. 2012..These results, which demonstrate that there are relevant immunologic differences between monomers and high-quality envelope trimers, have important implications for HIV-1 vaccine development... - Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeysWendy W Yeh
Division of Viral Pathogenesis, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
J Virol 86:7052-9. 2012..These findings indicate that early NAbs are directed toward SIVmac251 Env V4 but not the V1 region, and that this env vaccination regimen did not alter the kinetics or the breadth of NAbs during early infection... 
Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in MonkeysNorman L Letvin
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
Sci Transl Med 3:81ra36. 2011..This study begins to elucidate the mechanisms of vaccine protection against immunodeficiency viruses and highlights the need to analyze these immune and genetic correlates of protection in future trials of HIV vaccine strategies...- Limited contribution of mucosal IgA to Simian immunodeficiency virus (SIV)-specific neutralizing antibody response and virus envelope evolution in breast milk of SIV-infected, lactating rhesus monkeysSallie R Permar
Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115, USA
J Virol 84:8209-18. 2010.... - Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with DryvaxMichael S Seaman
Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
J Infect Dis 201:1353-60. 2010..To investigate this question, we examined the effect of immunization with modified vaccinia Ankara (MVA) on subsequent challenge with replication-competent vaccinia virus (Dryvax)... - Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeysMichael S Seaman
Beth Israel Deaconess Medical Center, Division of Viral Pathogenesis, 330 Brookline Ave./RE-113, Boston, MA 02215, USA
J Virol 79:2956-63. 2005..This study demonstrates that it is possible to generate protective immune responses by vaccination with genetically diverse isolates of HIV-1... - The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arraysJonathan S Duke-Cohan
Laboratory of Immunobiology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Vaccine 27:1154-65. 2009..Our findings have important implications both for design of new recombinant subunit vaccines as well as for methods of assaying the human antibody response utilizing recombinant proteins produced in vitro... - Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in miceDavid R Kaufman
Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
J Virol 82:6829-37. 2008..These studies also suggest that rAd vectors warrant further assessment as candidate subunit smallpox vaccines... - Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigsJoseph P Nkolola
Division of Vaccine Research, Beth Israel Deaconess Medical Center, E CLS 1047, 330 Brookline Avenue, Boston, MA 02215, USA
J Virol 84:3270-9. 2010.... - Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responsesKeith A Reimann
Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
J Virol 79:8878-85. 2005.... - Diverse cross-reactive potential and Vbeta gene usage of an epitope-specific cytotoxic T-lymphocyte population in monkeys immunized with diverse human immunodeficiency virus type 1 Env immunogensSandrine L Hulot
Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, Massachusetts 02215, USA
J Virol 83:9803-12. 2009.... - Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccinesShawn M Sumida
Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
J Clin Invest 114:1334-42. 2004..Synergistic recruitment and expansion of DCs in vivo may prove a practical strategy for overcoming this limitation and potentiating immune responses to vaccines as well as other immunotherapeutic strategies... - International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populationsDan H Barouch
Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
Vaccine 29:5203-9. 2011..These data inform the clinical development of alternative serotype rAd vaccine vectors in the developing world... - Robust vaccine-elicited cellular immune responses in breast milk following systemic simian immunodeficiency virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeysAndrew B Wilks
Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA
J Immunol 185:7097-106. 2010.... - Impact of anti-orthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune responsesStephen R Walsh
Division of Infectious Diseases, Brigham and Women s Hospital, Boston, MA 02115, United States
Vaccine 31:114-9. 2012..The controls used in this study were the empty vectors (MVA and FPV)... - Thy1+ NK [corrected] cells from vaccinia virus-primed mice confer protection against vaccinia virus challenge in the absence of adaptive lymphocytesGeoffrey O Gillard
Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America
PLoS Pathog 7:e1002141. 2011..These results demonstrate that a defined innate memory cell population alone can provide host protection against a lethal systemic infection through viral clearance... - Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeysNorman L Letvin
Vaccine Research Center, National Institutes of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland 20892 3005, USA
J Virol 78:7490-7. 2004.... - Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivityHillel Haim
Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Division of AIDS, Harvard Medical School, Boston, Massachusetts, United States of America
PLoS Pathog 7:e1002101. 2011.... - Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelopeCraig S Pace
Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016, USA
J Acquir Immune Defic Syndr 62:1-9. 2013..Here, we sought to assess ibalizumab antiviral breadth and potency and to identify determinants of natural preexisting resistance... - Subsets of memory cytotoxic T lymphocytes elicited by vaccination influence the efficiency of secondary expansion in vivoMichael S Seaman
Department of Medicine, Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
J Virol 78:206-15. 2004..These observations suggest that CTL-based vaccines should elicit central memory rather than effector memory T cells and illustrate the importance of monitoring the phenotype and functionality of vaccine-induced, antigen-specific CTL... - Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibodyMichael M Freeman
Division of Molecular Medicine, Children s Hospital, and Department of Pediatrics, Harvard Medical School, 3 Blackfan Circle, Boston, MA 02115, USA
Structure 18:1632-41. 2010..These results could guide CD4-based immunogen design and lead to a better understanding of HIV-1 entry...